APA (7th ed.) Citation

D, L., AM, H., E, S., L, L., RJ, B., Langleben, D., . . . Barst, R. J. (2004). Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: A 1-year follow-up study. CHEST, 126(4), 1377. https://doi.org/10.1378/chest.126.4.1377

Chicago Style (17th ed.) Citation

D, Langleben, et al. "Sustained Symptomatic, Functional, and Hemodynamic Benefit with the Selective Endothelin-A Receptor Antagonist, Sitaxsentan, in Patients with Pulmonary Arterial Hypertension: A 1-year Follow-up Study." CHEST 126, no. 4 (2004): 1377. https://doi.org/10.1378/chest.126.4.1377.

MLA (9th ed.) Citation

D, Langleben, et al. "Sustained Symptomatic, Functional, and Hemodynamic Benefit with the Selective Endothelin-A Receptor Antagonist, Sitaxsentan, in Patients with Pulmonary Arterial Hypertension: A 1-year Follow-up Study." CHEST, vol. 126, no. 4, 2004, p. 1377, https://doi.org/10.1378/chest.126.4.1377.